Basilea Presents Anti-Infective Pipeline and Late-Stage Development Plans

Bitget2026/10/27 06:10

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Basilea reported Cresemba in-market sales of USD 817 million for July 2025-June 2026, up 25% year over year.
Fosmanogepix phase 3 studies are ongoing in invasive candidiasis and invasive mold infections.
Ceftibuten-ledaborbactam's phase 2/3 program in complicated urinary tract infections is scheduled to start in mid-2027.
Zevtera's US market exclusivity runs until April 2034, supporting its long-term growth opportunity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Basilea Pharmaceutica AG published the original content used to generate this news brief on October 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Basilea Presents Anti-Infective Pipeline and Late-Stage Development Plans

You may also like

Crypto prices